InteloMed, Inc. to Exhibit Non-Invasive Cardiovascular Monitoring Platform for Assessing Dialysis Tolerance at the American Society of Nephrology's Kidney Week

PITTSBURGH, PA--(Marketwired - Nov 3, 2015) - InteloMed, Inc., an emerging leader and developer of software and informatics for non-invasive cardiovascular monitoring, will be exhibiting the CVInsight™ Platform for assessing dialysis treatment tolerance at the American Society of Nephrology's annual Kidney Week meeting in San Diego, CA November 5-8, 2015. Kidney Week is the world's largest clinical and scientific nephrology forum, bringing physicians, scientists, clinicians, and vendors together for in depth discussions on a broad range of nephrology topics.

In addition, Peter DeOreo, MD, Chief Medical Officer at the Centers for Dialysis Care (CDC) and his clinical team will present findings of their clinical quality demonstration project entitled Fluid Management with Photoplethysmographic Assisted Probing. The results of the project featuring the CVInsight™ Platform will be presented during the poster presentation session on Thursday, November 5 from 10:00 am to 12:00 noon Pacific Time. 

"Kidney Week is the leading scientific meeting for the nephrology community, so we are extremely enthusiastic to demonstrate our unique CVInsight™ Platform to this important group of clinicians and hear Dr. DeOreo present the findings from the clinical study conducted at Centers for Dialysis Care," stated Jill Schiaparelli, InteloMed President and CEO.

Demonstrations of the CVInsight™ Platform will be available in the scientific expo hall at the InteloMed booth, number 1607. The CVInsight™ Platform is an easy-to-use multi-parameter system that provides clinicians with non-invasive, real-time, dynamic and actionable information about a patient's cardiovascular stability and tolerance to the dialysis treatment. The system offers customized alerts that support each center's protocols, and provides indications to clinical staff members, allowing them to intervene and make adjustments during therapy. 

About InteloMed
InteloMed is redefining the standard of care in cardiovascular monitoring and informatics through its intelligent multi-dimensional, non-invasive CVInsight™ platform. The CVInsight™ platform provides real-time insights to inform clinical decisions in a variety of healthcare applications, including hospital and out-patient facilities, clinics, medical facilities and sleep labs. 

InteloMed is headquartered in Wexford, PA. 

For more information, visit us at www.InteloMed.com.

About ASN Kidney Week
The American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients. Kidney Week is the world's premier nephrology meeting, providing participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field. For more information, visit www.asn-online.org

Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.